COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure

mBio. 2020 May 22;11(3):e00946-20. doi: 10.1128/mBio.00946-20.

Authors

Eftychios Siniorakis¹, Spyridon Arvanitakis², Ioannis Nikolopoulos³, Maximilianos Elkouris⁴

Affiliations

¹ Department of Cardiology, Sotiria Chest Diseases Hospital, Athens, Greece.
² Department of Cardiology, Sotiria Chest Diseases Hospital, Athens, Greece sarvanitakis@doctors.org.uk.
³ Second Department of Infectious Diseases, Sotiria Chest Diseases Hospital, Athens, Greece.
⁴ Department of Clinical Biochemistry, Sotiria Chest Diseases Hospital, Athens, Greece.

No abstract available

Publication types

Letter

MeSH terms

Angiotensin Receptor Antagonists / pharmacology
Angiotensin Receptor Antagonists / therapeutic use
Angiotensin-Converting Enzyme 2
Betacoronavirus / isolation & purification
COVID-19
Coronavirus Infections / epidemiology
Coronavirus Infections / physiopathology*
Coronavirus Infections / virology
Heart Failure / enzymology
Heart Failure / physiopathology
Heart Failure / virology*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Pandemics
Peptidyl-Dipeptidase A / metabolism
Pneumonia, Viral / epidemiology
Pneumonia, Viral / physiopathology*
Pneumonia, Viral / virology
Renin-Angiotensin System / drug effects
Renin-Angiotensin System / physiology*
SARS-CoV-2

Substances

Angiotensin Receptor Antagonists
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Peptidyl-Dipeptidase A
ACE2 protein, human
Angiotensin-Converting Enzyme 2